Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

UCSF Helen Diller Family Comprehensive Cancer Center

Considerations for mitigating CAR-T resistance in multiple myeloma 2:57
Considerations for mitigating CAR-T resistance in multiple myeloma
Thomas Martin • 11 Sep 2023
IKEMA long-term sub-group analysis: Isa-Kd for 1q21+ multiple myeloma 4:03
IKEMA long-term sub-group analysis: Isa-Kd for 1q21+ multiple myeloma
Thomas Martin • 11 Sep 2023
Myeloma highlights from SOHO 2023: updates with the use of novel targeted immunotherapies 9:52
Myeloma highlights from SOHO 2023: updates with the use of novel targeted immunotherapies
Thomas Martin • 11 Sep 2023
Challenges with the real-world use of CAR-T therapy in multiple myeloma 4:14
Challenges with the real-world use of CAR-T therapy in multiple myeloma
Thomas Martin • 11 Sep 2023
Updates from the IKEMA trial: Isa-Kd versus Kd in R/R multiple myeloma 1:33
Updates from the IKEMA trial: Isa-Kd versus Kd in R/R multiple myeloma
Thomas Martin • 30 Sep 2022
The value of CAR-T cell therapy for the treatment of R/R multiple myeloma 2:00
The value of CAR-T cell therapy for the treatment of R/R multiple myeloma
Thomas Martin • 30 Sep 2022
Unmet needs and unanswered questions in multiple myeloma 3:25
Unmet needs and unanswered questions in multiple myeloma
Thomas Martin • 30 Sep 2022
Novel transplant and post-transplant options in ALL 3:02
Novel transplant and post-transplant options in ALL
Aaron Logan • 13 Sep 2021
Transplant optimization strategies 1:40
Transplant optimization strategies
Aaron Logan • 13 Sep 2021
Optimizing post-transplant outcomes 2:11
Optimizing post-transplant outcomes
Aaron Logan • 13 Sep 2021
From myeloma precursors to late relapses, where do BiTEs fit? 4:25
From myeloma precursors to late relapses, where do BiTEs fit?
Thomas Martin • 22 Apr 2021
Changing treatment approaches for transplant-ineligible myeloma: DRd, BiTEs and CAR-T 2:59
Changing treatment approaches for transplant-ineligible myeloma: DRd, BiTEs and CAR-T
Thomas Martin • 22 Apr 2021
Moving forward: bringing CAR-T therapy to a frontline setting in myeloma 2:18
Moving forward: bringing CAR-T therapy to a frontline setting in myeloma
Thomas Martin • 22 Apr 2021
Novel targets and dual-targeting approaches in myeloma 2:53
Novel targets and dual-targeting approaches in myeloma
Thomas Martin • 22 Apr 2021
CARTITUDE-1: cilta-cel improves HRQoL for patients with myeloma 2:09
CARTITUDE-1: cilta-cel improves HRQoL for patients with myeloma
Thomas Martin • 9 Mar 2021
IKEMA: isatuximab addition to Kd improves depth of response in myeloma 2:34
IKEMA: isatuximab addition to Kd improves depth of response in myeloma
Thomas Martin • 9 Mar 2021
The content of VJHemOnc is intended for healthcare professionals